Expired activity
Please go to the PowerPak
homepage and select a course.
Immunotherapy in the Treatment Arsenal for Small Cell Lung Cancer, and Managed Care Implications for the "Four Ps": Patient, Provider, Pharmacy, and Plan
This CPE activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an independent educational grant from AstraZeneca.
Activity Description
For over three decades, almost no treatment advances were made in small cell lung cancer (SCLC) until checkpoint inhibitors finally propelled the SCLC treatment landscape forward with several recent regulatory approvals. More developments are expected in the near future on the SCLC treatment landscape.
This PeerView activity will provide managed care professionals with a foundational overview of how cancer immunotherapies work and why/how this class of agents is different from other agents used in oncology, why they have revolutionized the management of cancer over the last few years, and how the management of SCLC is finally changing as a result of these therapies. In addition, the latest research and practical considerations for value assessment of cancer immunotherapies in managed care settings will be presented, with specific implications for SCLC. Practical guidance will be provided for incorporating the latest clinical advances in immuno-oncology related to SCLC into benefit design, seamless drug distribution and dispensing, maximal patient safety, and effective communication with patients and care team clinicians.
Target Audience
This activity has been designed to meet the educational needs of managed care pharmacists, medical directors, payer physicians, nurse case managers, and other healthcare professionals in managed care settings.
Educational Objectives
Upon completion of this activity, participants will be able to:
- Describe the rationale for and potential benefits of integrating immunotherapies and immune-based combination approaches into the SCLC treatment arsenal throughout the disease continuum
- Review efficacy and safety findings from key clinical trials assessing immunotherapies and combination approaches across different treatment settings of SCLC, as well as data on potential biomarkers
- Incorporate immunotherapies into treatment plans for appropriate patients with SCLC in managed care settings
Continuing Pharmacy Education
The Medical Learning Institute, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Medical Learning Institute, Inc. (MLI) designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-9999-21-041-H01-P
Type of Activity: Knowledge
Release Date
November 12, 2020
Expiration Date
December 18, 2021
Faculty Disclosures
Co-Chair & Presenter
Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
Stephen V. Liu, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Apollomics, Inc.; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Guardant Health, Inc.; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Merck & Co., Inc./MSD; Pfizer, Inc.; PharmaMar; Regeneron; Taiho; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Alkermes; AstraZeneca; Bayer; Blueprint Medicines Corporation; Bristol Myer Squibb; Corvus Pharmaceuticals; Genentech, Inc./F. Hoffmann-La Roche Ltd; Lilly; Lycera; Merus; Merck & Co., Inc./MSD; Molecular Partners; Pfizer, Inc.; Rain Therapeutics, Inc.; RAPT Therapeutics; Spectrum Pharmaceuticals, Inc.; and Turning Point Therapeutics. Grant/Research Support goes to Institution.
Co-Chair & Presenter
Bhavesh Shah, RPh, BCOP
Boston Medical Center Health System
Boston, Massachusetts
Bhavesh Shah, RPh, BCOP, has no financial interests/relationships or affiliations in relation to this activity.
Planning Committee Disclosures
Tracy L. Greene, MSN, RN, FNP-C, Nurse Planner, MLI, has nothing to disclose.
Teresa Haile, RPh, MBA, Pharmacy Planner, MLI, has nothing to disclose.
The planners from Medical Learning Institute, Inc., the accredited provider, and PVI, PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.
Content/Peer Reviewer Disclosures
The following Content/Peer Reviewers have nothing to disclose:
Shaina Rozell, MD, MPH
Pamela Ash, RN, MSN, CBCN
Patricia A. Ensor, RPh, MBA
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Method of Participation
There are no fees for participating in or receiving credit for this accredited activity. For
information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from
email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.
Please note that if you are requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number & DOB (MM/DD). A score of 70% or higher is needed to obtain MOC credit.
For nurses, in order to receive a CNE Statement of Credit, answers to all post-test questions are also required. A score of 70% or higher is needed to obtain CNE credit.
For pharmacists, Medical Learning Institute, Inc. will accept your completed evaluation from up to 30 days following participation and will report your participation in this educational activity to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks of participation, you will receive a confirmation email and can then view your participation record at the NABP website: mycpemonitor.net.
About This CPE Activity
PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.
